Abbvie Inc. trumped Allergan plc in the effort to treat women with abnormal bleeding due to uterine fibroids. Abbvie, of North Chicago, reported top-line data from the phase III ELARIS UF-EXTEND extension study, which showed that, at 12 months, elagolix (300 mg twice daily), in combination with low-dose hormone (add-back) therapy (estradiol 1.0 mg/norethindrone acetate 0.5 mg), reduced heavy menstrual bleeding, with 87.9 percent of women with uterine fibroids achieving clinical response.